For decades, hundreds of thousands of infants weighing less than five kilograms have been dying from malaria without a single drug specifically designed for their tiny bodies. These young lives, the most vulnerable to the parasitic disease, lacked appropriate treatment formulations for their specific weight and physiological needs.
Malaria continues to claim hundreds of thousands of young lives annually, but a tailored treatment for the most vulnerable newborns has only just been prequalified by the World Health Organization.
Based on this prequalification, a significant reduction in malaria-related infant mortality is now possible, provided global health organizations and governments ensure rapid and widespread access to Coartem Baby.
Novartis' Coartem Baby, an antimalarial developed for newborns and young infants weighing 2 to 5 kilograms, has received prequalification from the World Health Organization (WHO), according to BioSpectrum Asia. The prequalification marks a critical milestone in addressing a long-neglected patient group with a tailored treatment.
The First Tailored Treatment for Tiny Lives
Coartem Baby, also known as Riamet® Baby, is the first and only antimalarial specifically developed for infants weighing 2 to 5 kilograms, according to BioSpectrum Asia and Novartis. The specialized formulation targets a previously underserved and highly vulnerable population, marking a significant advancement in pediatric malaria care.
WHO Approval Process for Antimalarial Drugs
The World Health Organization (WHO) prequalified Coartem® (artemether-lumefantrine) Baby on April 24, 2026, according to Novartis. The official regulatory milestone, though reported as current by some, confirms the drug's global recognition and enables broader access for newborns and young infants.
Malaria's Ongoing Impact on Infants
The global malaria burden remained substantial in 2023, with 249 million reported cases and 608,000 deaths, according to the World Health Organization. Malaria disproportionately affects young children in endemic regions. Novartis has delivered over 1.1 billion treatment courses of its antimalarial Coartem since 1999, yet the persistent high mortality rates highlight the critical need for targeted innovations like Coartem Baby.
Ensuring Access to New Antimalarial Drugs
The WHO prequalification of Coartem Baby should accelerate its availability and integration into national malaria control programs, according to Latest news from Azerbaijan. The prequalification streamlines procurement, but rapid distribution remains crucial to reduce infant malaria mortality. The drug's belated arrival, despite Novartis' extensive history with Coartem, exposes a systemic failure in pharmaceutical development: market incentives alone are insufficient for niche, high-need pediatric populations, demanding stronger public health mandates.
By late 2026, the widespread deployment of Novartis' Coartem Baby could begin to alter the demographic profile of malaria mortality, particularly among infants weighing 2 to 5 kilograms, according to Novartis.
